Skip to main content
Erschienen in: Cancer Causes & Control 10/2014

01.10.2014 | Original paper

Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma

verfasst von: Shaowei Wu, Helen Kuo, Wen-Qing Li, Alvaro Laga Canales, Jiali Han, Abrar A. Qureshi

Erschienen in: Cancer Causes & Control | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Previous studies suggest that solar UV exposure in early life is predictive of cutaneous melanoma risk in adulthood, whereas the relation of BRAF mutation with sun exposure and disease prognosis has been less certain. We investigated the associations between BRAFV600E and NRASQ61R mutations and known risk factors, clinicopathologic characteristics and clinical outcomes of melanoma in a case series of primary invasive cutaneous melanoma from the Nurses’ Health Study (NHS).

Methods

Somatic BRAFV600E and NRASQ61R mutations of 127 primary invasive melanomas from the NHS cohort were determined by pyrosequencing using formalin-fixed, paraffin-embedded block tissues. Logistic regression analyses were performed to detect the associations of mutations with melanoma risk factors, and Kaplan–Meier method was used to examine associations between mutations and survival.

Results

The odds ratios for harboring BRAFV600E mutations were 5.54 (95 % CI 1.19–25.8, p trend = 0.02) for women residing in states with UV index ≥ 7 versus those residing in states with UV index ≤5 at 30 years of age. Patients with BRAFV600E mutations tended to have shorter melanoma-specific survival when compared to patients with wild type at both loci (median survival time 110 vs. 159 months) (p = 0.03). No association was found between NRASQ61R mutation and melanoma risk factors or melanoma-specific survival.

Conclusions

BRAFV600E mutations in primary cutaneous melanomas were associated with residence in locations with medium and high UV indices in mid-life. BRAFV600E mutation may be associated with an unfavorable prognosis among melanoma patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Geller AC, Miller DR, Annas GD et al (2002) Melanoma incidence and mortality among US whites, 1969–1999. JAMA 288:1719–1720PubMedCrossRef Geller AC, Miller DR, Annas GD et al (2002) Melanoma incidence and mortality among US whites, 1969–1999. JAMA 288:1719–1720PubMedCrossRef
2.
Zurück zum Zitat Jemal A, Devesa SS, Hartge P et al (2001) Recent trends in cutaneous melanoma incidence among Whites in the United States. J Natl Cancer Inst 93:678–683PubMedCrossRef Jemal A, Devesa SS, Hartge P et al (2001) Recent trends in cutaneous melanoma incidence among Whites in the United States. J Natl Cancer Inst 93:678–683PubMedCrossRef
3.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
4.
Zurück zum Zitat Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41:28–44PubMedCrossRef Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41:28–44PubMedCrossRef
5.
Zurück zum Zitat Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41:2040–2059PubMedCrossRef Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41:2040–2059PubMedCrossRef
6.
Zurück zum Zitat Hacker E, Hayward NK, Dumenil T et al (2010) The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol 130(1):241–248PubMedCrossRef Hacker E, Hayward NK, Dumenil T et al (2010) The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol 130(1):241–248PubMedCrossRef
7.
Zurück zum Zitat Qureshi AA, Zhang M, Han J (2011) Heterogeneity in host risk factors for incident melanoma and non-melanoma skin cancer in a cohort of US women. J Epidemiol 21(3):197–203PubMedCentralPubMedCrossRef Qureshi AA, Zhang M, Han J (2011) Heterogeneity in host risk factors for incident melanoma and non-melanoma skin cancer in a cohort of US women. J Epidemiol 21(3):197–203PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41:45–60PubMedCrossRef Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41:45–60PubMedCrossRef
9.
Zurück zum Zitat Whiteman DC, Watt P, Purdie DM et al (2003) Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 95:806–812PubMedCrossRef Whiteman DC, Watt P, Purdie DM et al (2003) Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 95:806–812PubMedCrossRef
10.
Zurück zum Zitat Whiteman DC, Stickley M, Watt P et al (2006) Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 24:3172–3177PubMedCrossRef Whiteman DC, Stickley M, Watt P et al (2006) Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 24:3172–3177PubMedCrossRef
11.
Zurück zum Zitat Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147PubMedCrossRef Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147PubMedCrossRef
12.
Zurück zum Zitat Landi MT, Bauer J, Pfeiffer RM et al (2006) MC1R germline variants confer risk for BRAF -mutant melanoma. Science 313:521–522PubMedCrossRef Landi MT, Bauer J, Pfeiffer RM et al (2006) MC1R germline variants confer risk for BRAF -mutant melanoma. Science 313:521–522PubMedCrossRef
13.
Zurück zum Zitat Maldonado JL, Fridlyand J, Patel H et al (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878–1890PubMedCrossRef Maldonado JL, Fridlyand J, Patel H et al (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878–1890PubMedCrossRef
14.
Zurück zum Zitat Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef
15.
Zurück zum Zitat Goydos JS, MannB Kim HJ et al (2005) Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 200:362–370PubMedCrossRef Goydos JS, MannB Kim HJ et al (2005) Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 200:362–370PubMedCrossRef
16.
Zurück zum Zitat van Elsas A, Zerp SF, van der Flier S et al (1996) Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149:883–893PubMedCentralPubMed van Elsas A, Zerp SF, van der Flier S et al (1996) Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149:883–893PubMedCentralPubMed
17.
Zurück zum Zitat Ellerhorst JA, Greene VR, Ekmekcioglu S et al (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17(2):229–235PubMedCentralPubMedCrossRef Ellerhorst JA, Greene VR, Ekmekcioglu S et al (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17(2):229–235PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Campbell PM, Der CJ (2004) Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 14:105–114PubMedCrossRef Campbell PM, Der CJ (2004) Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 14:105–114PubMedCrossRef
19.
Zurück zum Zitat Meier F, Schittek B, Busch S et al (2005) The RAS/RAF/MEK/ERK and PI3 K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10:2986–3001PubMedCrossRef Meier F, Schittek B, Busch S et al (2005) The RAS/RAF/MEK/ERK and PI3 K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10:2986–3001PubMedCrossRef
20.
Zurück zum Zitat Kudchadkar RR, Smalley KS, Glass LF et al (2013) Targeted therapy in melanoma. Clin Dermatol 31(2):200–208PubMedCrossRef Kudchadkar RR, Smalley KS, Glass LF et al (2013) Targeted therapy in melanoma. Clin Dermatol 31(2):200–208PubMedCrossRef
21.
Zurück zum Zitat Edlundh-Rose E, Egyhazi S, Omholt K et al (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471–478PubMedCrossRef Edlundh-Rose E, Egyhazi S, Omholt K et al (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471–478PubMedCrossRef
22.
Zurück zum Zitat Autier P, Doré JF (1998) Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer. Int J Cancer 77(4):533–537PubMedCrossRef Autier P, Doré JF (1998) Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer. Int J Cancer 77(4):533–537PubMedCrossRef
23.
Zurück zum Zitat Qureshi AA, Laden F, Colditz GA et al (2008) Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med 168(5):501–507PubMedCrossRef Qureshi AA, Laden F, Colditz GA et al (2008) Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med 168(5):501–507PubMedCrossRef
24.
Zurück zum Zitat Whiteman DC, Whiteman CA, Green AC (2001) Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 12:69–82PubMedCrossRef Whiteman DC, Whiteman CA, Green AC (2001) Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 12:69–82PubMedCrossRef
25.
Zurück zum Zitat Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164(4):776–784PubMedCrossRef Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164(4):776–784PubMedCrossRef
26.
Zurück zum Zitat Thomas NE, Edmiston SN, Alexander A et al (2007) Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 16:991–997PubMedCrossRef Thomas NE, Edmiston SN, Alexander A et al (2007) Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 16:991–997PubMedCrossRef
27.
Zurück zum Zitat Venesio T, Chiorino G, Balsamo A et al (2008) In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol 21:716–726PubMedCrossRef Venesio T, Chiorino G, Balsamo A et al (2008) In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol 21:716–726PubMedCrossRef
28.
Zurück zum Zitat Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R et al (2007) Distinct clinical and pathological features are associated with the BRAF (T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 127(4):900–905PubMedCrossRef Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R et al (2007) Distinct clinical and pathological features are associated with the BRAF (T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 127(4):900–905PubMedCrossRef
29.
Zurück zum Zitat Thomas NE, Berwick M, Cordeiro-Stone M (2006) Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J Invest Dermatol 126:1693–1696PubMedCrossRef Thomas NE, Berwick M, Cordeiro-Stone M (2006) Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J Invest Dermatol 126:1693–1696PubMedCrossRef
30.
Zurück zum Zitat Willmore-Payne C, Holden JA, Tripp S, Layfield LJ (2005) Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36(5):486–493PubMedCrossRef Willmore-Payne C, Holden JA, Tripp S, Layfield LJ (2005) Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36(5):486–493PubMedCrossRef
31.
Zurück zum Zitat Poynter JN, Elder JT, Fullen DR et al (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16(4):267–273PubMedCrossRef Poynter JN, Elder JT, Fullen DR et al (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16(4):267–273PubMedCrossRef
32.
Zurück zum Zitat Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246PubMedCrossRef Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246PubMedCrossRef
33.
Zurück zum Zitat Devitt B, Liu W, Salemi R et al (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24(4):666–672PubMedCrossRef Devitt B, Liu W, Salemi R et al (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24(4):666–672PubMedCrossRef
34.
Zurück zum Zitat Akslen LA, Angelini S, Straume O et al (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125:312–317PubMed Akslen LA, Angelini S, Straume O et al (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125:312–317PubMed
35.
Zurück zum Zitat Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516PubMedCentralPubMedCrossRef Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114PubMedCrossRef Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114PubMedCrossRef
37.
Zurück zum Zitat Sivertsson A, Platz A, Hansson J, Lundeberg J (2002) Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. Clin Chem 48:2164–2170PubMed Sivertsson A, Platz A, Hansson J, Lundeberg J (2002) Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. Clin Chem 48:2164–2170PubMed
Metadaten
Titel
Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma
verfasst von
Shaowei Wu
Helen Kuo
Wen-Qing Li
Alvaro Laga Canales
Jiali Han
Abrar A. Qureshi
Publikationsdatum
01.10.2014
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 10/2014
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0443-x

Weitere Artikel der Ausgabe 10/2014

Cancer Causes & Control 10/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.